Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 600 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR How Are Eligibility Criteria for Clinical Trials Changing to Help People... June 10, 2021 News digest – calorie guidelines, reduced lung cancer referrals and COVID-19’s... September 19, 2020 Sun Exposure Lowers Risk of Breast Cancer, Study Finds January 6, 2022 How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... October 12, 2023 Load more HOT NEWS 2023 ASCO Annual Meeting Research Round Up: Improving Symptom Monitoring and... Firefighters Band Together To Raise $30k For Breast Cancer Research &... New study to investigate breast cancer in ethnic minority groups Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes
